P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis.
- Author:
Jin-liang WANG
1
;
Shun-chang JIAO
;
Ping YE
;
Jin-yu LI
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; metabolism; pathology; Cisplatin; therapeutic use; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; drug therapy; metabolism; pathology; Tumor Suppressor Protein p53; biosynthesis
- From: Journal of Southern Medical University 2008;28(5):770-773
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the relation between p53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer (NSCLC).
METHODSThe DerSimonian-Laird random effect model was used to analyze the data reported in relevant literature.
RESULTSSixteen trials involving 1070 patients were retrieved. The overall positivity rate of p53 was 50.4% and overall response rate to cisplatin was 38.7%. The test for heterogeneity showed that all eligible studies had heterogeneity (chi 2-/+47.57, P<0.0001). The combined odds ratio (OR) was 1.37, with 95% confidence interval of 0.84-2.24.
CONCLUSIONExpression of p53 protein in patients with NSCLC is not associated with the chemosensitivity to cisplatin.
